O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, et al. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol 2020 Feb 18. pii: S0090-8258(20)30090.
PMID: 32081463